

Sandostatin

Band Name	Octreotide Acetate
Drug Type	Hormone
Indication	Hypoglycaemia secondary to hyperinsulinaemia before or after or instead of subtotal pancreatectomy for nesidioblastosis
Action	Long acting synthetic octapeptide analogue of somatostatin which inhibits insulin [growth hormone and glucagon] release.
Presentation	0.05mg [50mcg]/ml ampoule.
Storage	Store below 8 ⁰ C. Do not freeze.
Dose	5 microg/Kg/dose
Interval (hr)	8
Dilution	5-20 microg/kg/day, administered every 4-8 hours. Commence treatment with the lower dosage and frequency of administration. Maximum dose 40 microg/kg/day.
Administration	Subcutaneous injection or intravenous infusion
Side Effects	Vomiting and abdominal distention may occur Hyperglycaemia
Contraindications	
Other Considerations	Monitor BSL at least 4th hourly until regime has been stabilised.
References	<p>Barr P, Berry A. (1994). Drug Therapy in Newborn Infants - Prescribing Information. Sydney: Royal Alexandra Hospital for Children.</p> <p>Bhatt DR, Furman GI, Reber DJ, Wirtschafter DD, and Thomas JC. (1991) Neonatal Drug Formulary. (2nd ed). Los Angeles, California: Meade Johnson Pharmaceuticals NDF Publishing.</p>